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RNA aptamers as pathway-speci¢c MAP kinase inhibitors
Scott D Seiwert 1, Theresa Stines Nahreini 2, Stefan Aigner 1,
Natalie G Ahn 2 and Olke C Uhlenbeck 1
Background: In eukaryotic cells, many intracellular signaling pathways have
closely related mitogen activated protein kinase (MAPK) paralogs as central
components. Although MAPKs are therefore obvious targets to control the cellular
responses resulting from the activation of these signaling pathways, the
development of inhibitors which target speci¢c cell signaling pathways involving
MAPKs has proven dif¢cult.
Results: We used an RNA combinatorial approach to isolate RNAs that inhibit
the in vitro phosphorylation activity of extracellular regulated kinase 2 (ERK2).
These inhibitors block phosphorylation by ERK1 and ERK2, but do not inhibit Jun
N-terminal kinase or p38 MAPKs. Kinetic analysis indicates these inhibitors
function at high picomolar concentrations through the steric exclusion of substrate
and ATP binding. In one case, we identi¢ed a compact RNA structural domain
responsible for inhibition.
Conclusions: RNA reagents can selectively recognize and inhibit MAPKs
involved in a single signal transduction pathway. The methodology described here
is readily generalizable, and can be used to develop inhibitors of MAPKs involved
in other signal transduction pathways. Such reagents may be valuable tools to
analyze and distinguish homologous effectors which regulate distinct signaling
responses.
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Introduction
Mitogen activated protein kinases (MAPKs) are terminal
components of evolutionarily conserved protein-phosphor-
ylation cascades utilized in a diverse array of eukaryotic
signal transduction pathways. When activated, MAPKs
phosphorylate transcription factors, cytoskeletal proteins,
and other protein kinases and cellular components to pro-
mote pathway-speci¢c changes in cell physiology [1]. In
mammalian cells, different MAPKs are involved in specify-
ing responses which include cell proliferation, apoptosis,
and differentiation [1]. Inappropriate activation of speci¢c
MAPK pathways is associated with various disease states in
humans, including cancer [2] and autoimmune diseases [3].
Although events which lead to extracellular regulated ki-
nase 1/2 (ERK1/2) activation are understood, the molecular
targets of ERK1/2 which promote proliferative responses
are much less well de¢ned, re£ecting a general problem in
analyzing the changes in gene expression promoted by
signal transduction pathways. Clearly, techniques providing
a rapid and accessible means to develop inhibitors that
block speci¢c signal transduction pathways would be val-
uable to address this issue.
Despite their potential importance, the development of
inhibitors that target speci¢c MAPK pathways has been
dif¢cult due to the large number of highly related
MAPK variants. Mammalian cells contain at least 12
MAPK paralogs that comprise at least ¢ve sequence sub-
families [4]. At least three of these are associated with
distinct signaling pathways; the ERK1/2 and ERK5 sub-
families mediate growth factor signaling, while the c-JUN
N-terminal kinase/stress activated protein kinase (JNK/
SAPK) and the p38 MAPK subfamilies are implicated in
cell stress and in£ammatory responses. Two additional pro-
teins (ERK3a and ERK3b) comprise a sequence subfamily
that functions in signaling pathways not currently de-
¢ned.
Most of the small molecule inhibitors of protein kinases
produced thus far act as competitive inhibitors of ATP
binding [5^8]. Such inhibitors must derive their speci¢city
from the structural features of the evolutionarily conserved
ATP binding pocket which are unique to their particular
kinase target. Consequently, it has proven dif¢cult to pro-
duce small molecule inhibitors that can effectively discrim-
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inate between the estimated 2500 protein kinases present
in mammalian cells. For example, the speci¢city of pyridi-
nylimidazole compounds for p38K/L MAPKs depends
largely on the side chain size of a single amino acid in
the ATP binding pocket [9]. Any protein kinase that con-
tains an amino acid side chain of equivalent or smaller size
at the corresponding position (such as type II transforming
growth factor L receptor) are somewhat sensitive to these
compounds [10]. Thus, the development of more speci¢c
protein kinase inhibitors that target other structural ele-
ments in protein kinases could in principle provide greater
speci¢city of inhibition. Ideally, these inhibitors would rec-
ognize a complex, functionally important epitope unique to
all of the MAPK subfamily members involved in a single
cell signaling pathway.
In MAPKs, the ‘activation lip’ represents such a target.
The activation lip is found at the interface of the N- and
C-terminal folding domains and contains conserved threo-
nine and tyrosine residues whose phosphorylation activates
the kinase. Dual phosphorylation activates the kinase by
reorienting the two domains to align active site residues for
catalysis [11]. Thus, the activation lip is a crucial compo-
nent of MAPK function. Because the activation lip differs
in sequence between the various MAPK subfamilies in-
volved in different signal transduction pathways [4], it
therefore represents a potentially useful target for path-
way-speci¢c inhibitors.
Here, we describe the development of novel MAPK inhib-
itors targeted to the activation lip of ERK2. Our strategy
relied on an RNA combinatorial approach which allows
RNA molecules that perform a desired function to be iso-
lated from a large (V1014^1015) collection of random se-
quence RNA through iterative enrichment [12]. This
methodology has been previously exploited to identify
high af¢nity RNA ligands (RNA aptamers) to small mole-
cules and proteins. RNA aptamers that bind to enzymes
such as proteases [13], protein phosphatases [14], and pro-
tein kinases [15] can inhibit the function of their target in
vitro, making RNA iterative selection a useful means to
develop inhibitors of protein function. Since such RNA
aptamers can be expressed from cassettes in cultured cells
[16,17] and can function as inhibitors in vivo [18^20], this
Figure 1. Iterative RNA selection. (a) Iterative selection methodology. The initial RNA pool contained V2U1014 members. During the ¢rst
phase of iterative selection, the ppERK2 concentration was progressively reduced from 250 nM to 100 nM. In the second phase, the pool
RNA was incubated with unphosphorylated protein and nitrocellulose membrane capture was used to remove molecules that associated
with the unphosphorylated form of ERK2. After several steps of membrane capture in the presence of ERK2, the remainder of the RNA
pool was incubated with ppERK2 and RNAs capable of associating with ppERK2 were isolated, again by nitrocellulose membrane capture.
(b) RNA pool binding to phosphorylated and unphosphorylated ERK2. Percent of the initial and ¢nal RNA pool that associated with 1 nM
ppERK2 (blue) or 1 nM ERK2 (red) was assayed by capture of RNA^protein complexes on nitrocellulose membranes. % RNA pool
captured in the absence of protein is indicated (yellow). (c) RNA pool inhibition of ppERK2 catalyzed phosphorylation. In vitro
phosphorylation of 1.25 WM GST-ELK1 (blue) or 0.25 mg/ml MBP (purple) catalyzed by 10 nM ppERK2 contained 20 nM of the initial or
¢nal RNA pool, or no RNA. Data are expressed as the average relative rate (krel = kRNA/kno RNA) from two or more experiments and the
standard deviation between experiments is indicated. The lower extent of inhibition seen with the MBP substrate most likely re£ects its
ability to sequester RNA through nonspeci¢c electrostatic interactions due to its high pI (pI = 11). Therefore, the GST-ELK1 fusion protein
was used as substrate in all future experiments.
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In order to identify RNAs that recognize activated ERK2,
a library of DNA molecules containing 134 randomized
positions was constructed [21] and transcribed for use in
the initial round of an iterative selection scheme that had
two phases (Figure 1a). In the ¢rst phase of selection,
RNA molecules that bound to high (100 nM) concentra-
tions of the diphosphorylated form of ERK2 (ppERK2)
were enriched from the initial, random RNA pool. The
second phase of selection included a negative selection
step in order to remove RNAs that bound to the unphos-
phorylated form of ERK2, with the intent of isolating only
those RNAs that bound epitopes not shared by both forms
of the protein. Iterative selection was terminated when a
signi¢cant fraction of the RNA pool bound to 1 nM
ppERK2, but showed no binding to non-phosphorylated
ERK2 at the same concentration (Figure 1b).
To determine whether the ¢nal ppERK2 binding RNA
pool contained molecules that could inhibit the kinase ac-
tivity of ppERK2, the RNA pool was assayed for the ability
to inhibit ppERK2 catalyzed phosphorylation in vitro (Fig-
ure 1c). Phosphorylation of a GST-ELK1 fusion protein
catalyzed by 10 nM ppERK in the presence of 20 nM of
the ¢nal pool RNA displayed a relative rate of approxi-
mately 25% that observed in its absence. Similarly, phos-
phorylation of myelin basic protein (MBP) by ppERK2
displayed a relative rate of 53%. Importantly, the initial,
random sequence pool of RNA did not diminish the rate
of ppERK2 catalyzed phosphorylation of either protein
under identical conditions (Figure 1c). Thus, our selection
protocol was successful in enriching for RNA molecules
that inhibit phosphorylation catalyzed by ppERK2.
To identify the most potent inhibitors in the ¢nal pool of
RNA, individual RNAs comprising this pool were cloned
and assayed individually for their ability to inhibit ppERK2
catalyzed phosphorylation of MBP. Four of the 20 RNAs
screened were found to inhibit this reaction to an extent
greater than that displayed by the ¢nal RNA pool (data not
shown). Based on their sequences, these highly inhibitory
RNAs comprise two classes. Family I consisted of three
related members, while family II contained a single mem-
ber. Since the initial RNA library sampled only
V4.2U10365% of all possible random sequences, it is ex-
tremely unlikely that all three members of family I were
present in the initial RNA pool and therefore must have
arisen through PCR mutagenesis during the iterative selec-
tion procedure.
We examined the dissociation constants for both the un-
phosphorylated and diphosphorylated forms of ERK2 of
the family II RNA and the most potent family I RNA
(Figure 2 and data not shown). Family II RNA has a Kd
for ppERK2 of 4.7 nM whereas the Kd is approximately
10-fold higher for the unphosphorylated form of ERK2 (50
nM) (Figure 2). In contrast, family I RNA binds with
roughly the same af¢nity to both phosphorylated and un-
phosphorylated forms of ERK2 (Kd = 1.3 nM ppERK2,
Kd = 2.3 nM ERK2). The difference in af¢nity between
phosphorylated and unphosphorylated protein observed
Figure 2. Dissociation constants of family II RNA. Trace, 5P-end
labeled family II RNA was incubated with diphosphorylated or
unphosphorylated ERK2 over a protein concentration range from
2 WM to 5.6 pM. RNA^protein complexes were captured on
nitrocellulose membranes and data were analyzed as described
[31].
Table 1
Kinetic analysis of RNA inhibitorsa.
RNA family Substrate examined Inhibition type Ki (nM)
I GST-ELK1 competitive 0.3
II GST-ELK1 competitive 5.1
II ATPb competitive 16.1
aSee Figure 3 and Materials and methods for experimental details.
bATP concentration varied from 100 WM to 6.25 WM.
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with the family II RNA indicates that it derives part of its
binding energy from epitopes speci¢c to the phosphorylat-
ed protein.
Kinetic characterization
Kinetic analysis was used to assess the nature of the inhi-
bition promoted by the most potent family I and family II
RNA. For each RNA family, Km and Vmax values for
ppERK2 catalyzed phosphorylation of GST-ELK1 were
determined at saturating concentrations of ATP. Parallel
kinetic experiments were performed in the presence of
several different inhibitor concentrations. Lineweaver^
Burk analysis of these data indicates that both RNA fam-
ilies function as competitive inhibitors of substrate binding
since both affect the Km for the GST-ELK1 substrate (Fig-
ure 3a, Table 1). Thus, both inhibitors block association of
the protein substrate with ppERK2. Ki values for both
RNA families were obtained by plotting the line slopes
of the Lineweaver^Burk data relative to the inhibitor con-
centration (Figure 3b, Table 1). The most potent family I
inhibitor has a Ki of approximately 0.3 nM, while the fam-
ily II RNA displays a Ki of approximately 5.1 nM. As
expected, these values are similar to the dissociation con-
stants determined for family I and family II RNAs for
ppERK2 (1.3 nM and 4.7 nM, respectively). These values
also compare favorably with those displayed by small
molecule inhibitors of protein kinases. For example, the
pyridinylimidazole compound 4-(£uorophenyl)-2-(4-meth-
ylsul¢nylphenyl)-5-(4-pyridyl)-imidazole (SB203580) dis-
plays a Ki between 21 nM [6] and 34 nM [22] for p38.
Small molecule inhibitors of p38K/L, and of other protein
kinases generally, act by preventing the association of ATP
with their kinase target [5]. Therefore, we examined
whether the family II RNA aptamer also functioned as a
competitive inhibitor of ATP association with ppERK2.
Again, Km and Vmax values were measured at various con-
centrations of inhibitor, but in this case GST-ELK1 was
held at a high concentration as the concentration of ATP
was varied. Lineweaver^Burk analysis of these data dem-
onstrate that the family II RNA also behaves as a compet-
itive inhibitor of ATP binding (Table 1). However, the
apparent Ki ATP (16.1 nM) is approximately three times
greater than the Ki for GST-ELK1 (5.1 nM, Table 1).
This kinetic analysis suggests that our iterative RNA se-
lection protocol isolated an RNA inhibitor (family II) that
acts by preventing the binding of both substrate and ATP
to ppERK2, most likely through steric exclusion. Thus, the
RNA inhibitors that we report have a novel mechanism of
action relative to small molecule protein kinase inhibitors;
they increase the Km for the substrate as well as prevent
the ATP phosphoryl donor from interacting with ppERK2
(Figure 3, Table 1).
Inhibitor speci¢city
Human ERK1 (hERK1) is nearly identical in sequence to
rat ERK2 (rERK2) (99.1% identity) and functions along
with ERK2 in mediating growth factor signaling in mam-
malian cells [1]. To test whether either family of RNA
inhibitor could affect the activity of hERK1, family I and
Figure 3. Representative kinetic analysis of RNA inhibitors. (a) Lineweaver^Burk analysis of the effects of family I RNA. Initial rates of
ppERK2 catalyzed phosphorylation of GST-ELK1 were determined at substrate concentrations ranging from 1.25 WM to 160 nM, in the
presence of 0, 2, 5, or 20 nM family II RNA. ppERK2 was present at 0.5 nM. (b) Family I Ki determination. Line slopes for data in panel a
were calculated by linear regression and plotted relative to the concentration of inhibitor that generated the line slope; the X-intercept gives
3Ki .
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family II RNAs were assayed for their ability to inhibit
hERK1 catalyzed phosphorylation of the GST-ELK1 fu-
sion protein (Figure 4a). Both RNA families were equally
effective in inhibiting the phosphorylation catalyzed by
low (10 nM) concentrations of either hERK1 or rERK2
(Figure 4a). A pool of random sequence RNAs at this
same concentration had no effect on phosphorylation cata-
lyzed by hERK1 or by rERK2 (Figure 4a) as expected
(Figure 1c). Thus, the modest difference in sequence be-
tween these two proteins does not affect the association
and consequent functional inhibition by family I or family
II RNAs.
To determine whether either of the ppERK1/2 inhibitors
displayed inhibitory activity for members of the JNK/
SAPK or the p38 subfamilies of MAPKs, high levels
(0.1 WM) of activated murine p38K, rat JNK2, or rat
ERK2 were used for in vitro phosphorylation of the
GST-ELK1 substrate (Figure 4b). Reactions were carried
out in the absence of RNA, in the presence of 0.12 WM
family I or family II RNA, or at the same concentration of a
random sequence pool of RNA (Figure 4b). Importantly,
neither RNA family affected phosphorylation catalyzed by
p38K or JNK2 (Figure 4b). In contrast, both family I and
family II RNAs inhibited in vitro phosphorylation cata-
lyzed by ppERK2 under these conditions, as expected
given the Ki values for ppERK2 inhibition (Table 1). Ran-
dom sequence RNA at this same concentration did not
inhibit ppERK2-catalyzed phosphorylation (Figure 4b).
Thus, RNAs belonging to both sequence families inhibit
Figure 4. RNA inhibitors are speci¢c for
ERK1/2 MAPKs. All data are derived from
two or more measurements, but in some
cases errors are too small be visualized.
(a) ERK1/2 catalyzed phosphorylation. In
vitro phosphorylation of 1.25 WM GST-
ELK1 catalyzed by 10 nM activated ERK2
(blue) or 10 nM activated ERK1 (purple),
including 12 nM family I RNA, 12 nM
family II RNA, 12 nM initial RNA pool, or
no RNA. Data are expressed as average
relative rates (krel = kRNA/kno RNA) from two
or more experiments. (b) Phosphorylation
catalyzed by ERK2, JNK, and p38. In vitro
phosphorylation of 1.25 WM GST-ELK1
catalyzed by 0.1 WM activated ERK2
(blue), 0.1 WM activated JNK2 (orange), or
0.1 WM activated p38 (yellow) in the
presence of 0.12 WM family I RNA, 0.12
WM family II RNA, 0.12 WM of the initial
RNA pool, or without RNA present. Extent
of reaction is expressed as the average
fraction of the phosphorylation activity
observed in the absence of RNA seen in
two or more experiments.
Figure 5. Localization of family I and family II inhibitory domains.
Phosphorylation of 1.25 WM GST-ELK1 catalyzed by 10 nM ERK2
included full length family I or full length family II RNAs (189
nucleotides), or 3P truncated versions of each containing the 5P-
most 101 nucleotides (family I v3P and family II v3P, respectively)
at 20 nM. Data are expressed as average relative rates,
krel = kRNA/kno RNA from two experiments.
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the two MAPKs (ERK1/2) that function in the signaling
pathways mediating growth factor responses, but do not
target MAPKs in cell stress or in£ammatory signal trans-
duction pathways.
Several lines of evidence support the conclusion that the
family II inhibitor functions by interacting with the activa-
tion lip of ppERK1/2. First, family II preferentially asso-
ciates with the phosphorylated form of ERK2 over the
unphosphorylated form (Figure 2). Since conformational
changes upon phosphorylation are largely localized to the
activation lip and the P+1 speci¢city region of ERK2 (the
majority of the kinase structure is static) [11], the binding
preference for the phosphorylated form of the protein is
consistent with RNA interaction with the activation lip.
Second, family II blocks association of both the substrate
and ATP (Figure 3, Table 1), which bind in close proxim-
ity to the activation lip [11]. Third, family II inhibits two
different MAPKs with identical activation lip sequences
(Figure 4a), but does not inhibit MAPKs with divergent
sequences in this region (Figure 4b).
Family I associates with and inhibits ppERK at a lower
concentration than does family II (Figure 2, Table 1, and
data not shown), but functions in a different manner. In
contrast to family II, family I does not recognize the acti-
Figure 6. Analysis of the family II secondary structure. (a) Secondary structure model I. Mulford [23] predicted structure overlaid with
summary results of nuclease structure probing experiments shown in panel c. Blue dots = RNase T1 sensitivity, red dots = RNase T2
sensitivity, yellow dots = RNase V1 sensitivity. For each nuclease, solid dots, partially ¢lled dots, and open circles represent, respectively,
strong, medium, and weak nuclease sensitivity. Sequences shown in purple are common to all library members. Sequences in loops 1 and
2 that are complementary are highlighted in blue. (b) Secondary structure model II. Alternate structure formed if internal loops in structure I
instead form base pairs. (c) Structure probing by partial nuclease digestion. Digestions were performed under conditions in which family II
v3P inhibits ppERK2. Representative data are shown. 5P end labeled family II v3P RNA was partially digested with RNase T1 under
denaturing conditions (lane 1), or hydrolyzed with alkali (lanes 2 and 7) as markers. Partial nuclease digestion of family II v3P RNA with
RNase T1 (lane 3), RNase T2 (lane 4), or RNase V1 (lane 6) was performed under conditions in which this RNA inhibits ppERK2
catalyzed phosphorylation. Terminal loop, 3P-tail, and internal loops 1 and 2 (see panel a) are indicated with brackets.
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vation lip since it associates with phosphorylated and un-
phosphorylated ERK2 with roughly the same af¢nity (see
above). Thus, family I and family II inhibit ppERK2 by
targeting different aspects of kinase structure.
RNA structural characterization
In an attempt to determine which part of family I and
family II RNA was responsible for inhibition, truncated
versions of each were tested for their ability to inhibit
phosphorylation catalyzed by ppERK2 in vitro. As an ini-
tial means to localize inhibitory function, molecules con-
taining only the 5P half of the family I RNA or the family
II RNA were tested for inhibitory activity (Figure 5).
When ppERK2 was present at 10 nM, 20 nM of the family
II RNA or 20 nM of an RNA representing its 5P-most 101
nucleotides (family II v3P) were equally effective at inhib-
iting ppERK2 function. In contrast, an RNA resulting from
analogous truncation of family I RNA (family I v3P) did not
display the complete inhibitory activity possessed by its
parental RNA. No inhibitory activity was observed using
RNAs corresponding to the 3P half of either RNA family
(data not shown). Thus, the family II RNA has a relatively
Figure 7. RNA truncations of the family II inhibitor. (a) Structural models of family II v3P RNA. Alternative structural forms of the family II
v3P RNA are shown. The computer predicted structure, structure I, forms helix A (green). Structure II forms helix B (blue). RNA TR-A
(truncation-A) can form both structures. RNA TR-B and RNA TR-C can form only the lower and upper portions of structure I, respectively,
while RNA TR-D and RNA TR-E form the lower and upper portions, respectively, of structure II. (b) Inhibitory activity of truncated RNAs.
All data are derived from two or more measurements, but in some cases errors are too small be visualized. In vitro phosphorylation
reactions were carried out as in Figure 5, but contained the RNAs listed in panel a, the initial RNA pool, or no RNA.
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compact inhibitory region which is localized to its 5P-most
101 nucleotides, while the family I RNA has a less easily
identi¢able inhibitory region. Since family I does not bind
to structural features particular to ppERK2 (e.g., the acti-
vation lip), it may require a larger portion of the RNA in
order to promote a steric clash with protein substrate bind-
ing.
To investigate the family II RNA structural elements re-
quired for its inhibitory function, a computational model
for the P22 v3P RNA secondary structure was ¢rst gener-
ated ([23], structure I, Figure 6a). Family II v3P RNA is
predicted to consist of an extensive duplex with two large
internal loops; a portion of this duplex is formed by se-
quences common to all library members. Interestingly, the
two internal loops have regions that are complementary to
one another. Thus, the P22 v3P RNA could adopt an alter-
native structure in which the duplex between the internal
loops (stem A, Figure 6a) is disrupted and a portion of the
internal loops form an alternative duplex (stem B in struc-
ture II, Figure 6b).
To directly examine the solution structure of P22 v3P
RNA, it was subjected to partial digestion using nucleases
with a preference for either single or double stranded RNA
(Figure 6c). Regions of predicted duplex RNA common to
both structures are sensitive to RNase V1, a nuclease spe-
ci¢c for nucleotides that are in duplexes or that are
stacked. The predicted terminal loop and the 3P-tail also
common to both structures are sensitive to the single
strand-speci¢c nucleases RNase T1 and RNase T2. In
support of structure I, the predicted internal loops of struc-
ture I are also sensitive to RNase T1 and RNase T2 (Fig-
ure 6a). However, several nucleotide positions in these
loops are also sensitive to RNase V1. These same positions
form helix B in structure II (Figure 6b). Similarly, sequen-
ces comprising stem A in structure I and stem B in struc-
ture II are sensitive to both single and double strand-spe-
ci¢c nucleases (Figure 6a,b). Since our RNA selection
methodology did not require conformational homogeneity
of functional RNAs, our interpretation of these data is that
both structures exist in equilibrium in solution.
To determine which one of these two structures inhibited
ppERK2, additional truncations of the family II v3P RNA
were made to further localize the ppERK2 inhibitory do-
main. A mutant RNA that replaced the terminal loop and
three putative base pairs adjacent to it with a tetraloop and
also removed sequences common to all library members
was ¢rst constructed (RNA TR-A, Figure 7a). TR-A is still
capable of forming both of the alternative helices (stems A
and B) present in structure I and structure II, respectively.
This RNA inhibited ppERK2 activity in a manner nearly
identical to the family II v3P and the full length family II
Figure 8. Mutants of family II inhibitor. (a) Secondary structural model and mutations. Structure I is shown and mutations in stem A and
stem B are indicated as A series and B series mutations, respectively. (b) ppERK2 inhibition promoted by stem A mutants. All data are
derived from two or more measurements, but in some cases errors are too small be visualized. Phosphorylation of 1.25 WM GST-ELK1
catalyzed by 10 nM ERK2 measured with 20 nM TR-A or 20 nM mutant RNA as indicated, or without RNA. The double mutant A1,2
restores stem A base pairing. Data are expressed as average relative rates, krel = kRNA/kno RNA, from two experiments. (c) ppERK2 inhibition
promoted by stem B mutants. Same as in panel b, except the indicated RNAs were assayed. Double mutants that restore potential stem B
base pairs are B1,2 and B4,6.
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RNA (Figure 7b). More drastic truncations were made in
an attempt to associate ppERK2 inhibition with one of the
two alternative structures. However, RNAs representing
the lower or the upper portions of structure I (RNAs
TR-B and TR-C, respectively, Figure 7a) or the lower or
upper half of structure II (TR-D and TR-E, Figure 7a) all
failed to inhibit ppERK2 (Figure 7b). Thus, many of the
sequence and/or structural elements within TR-A are es-
sential for inhibitory activity.
To examine directly the importance of stems A and B for
ppERK2 inhibitory activity, mutations that disrupted each
stem were introduced into TR-A (Figure 8a). Disruption of
putative stem A by changing the sequence of either strand
(mutations A1 and A2, Figure 8a) resulted in a complete
loss of inhibitory function (Figure 8b). Restoration of po-
tential base pairing in stem A upon combining these two
mutations (A1,2) resulted in an RNA that possessed inhib-
itory activity, albeit slightly reduced (Figure 8b). Thus,
stem A is a required structural component of the family
II RNA but its particular sequence is not. In contrast,
mutations based upon structure II that disrupt putative
stem B (B1, B2, B4 and B6) reduced, but did not com-
pletely eliminate, ppERK2 inhibition (Figure 8c). Muta-
tions in the 5P portion of the putative stem (B1 and B4)
affected inhibitory activity the least (each displaying a
krel = 0.51), while mutations in the 3P portion (B2 and B6)
had the greatest impact (krel = 0.84 and 0.66 for B2 and B6,
respectively). Thus, the identities of these sequences are
of differing importance, but both are nevertheless nones-
sential determinants of ppERK2 inhibition. Double mu-
tants that restored the potential for stem B base pairing
(B1,2; B4,6) failed to restore further ppERK2 inhibition
(Figure 8b), suggesting that stem B is not a structural el-
ement required for ppERK2 inhibition. The sum of these
mutagenesis data suggest that structure I is the functional
motif. However, we cannot exclude the possible formation
of a pseudoknotted RNA structure [24] in which both
stems A and B form simultaneously since such a structure
may require a speci¢c nucleotide sequence in putative
stem B [25].
Signi¢cance
All mitogenic stimuli are thought to activate the evolutio-
narily conserved RAS-RAF-MKK1/2-ERK1/2 pathway, and
oncogenic alleles of RAS are found in greater than 50% of
all colon carcinomas [2]. Despite a detailed understanding
of the MAPK signal transduction cascade, the global
changes in gene expression promoted by ERK1/2 that re-
sult in proliferative responses remain unknown. Speci¢c
inhibitors of ERK1/2 in conjunction with genome-wide
expression pro¢ling techniques would be invaluable tools
to address such issues. Here, we report the in vitro char-
acterization of RNA inhibitors of ppERK1/2, the ¢rst in-
hibitors developed that display speci¢city for these two
kinases. The ppERK1/2 inhibitors described here will be
useful tools in probing the functions of growth factor regu-
lated MAPK pathways in vivo.
The approach we have used to develop ppERK1/2 inhib-
itors is readily generalizable and can be used to develop
inhibitors of any chosen kinase provided it is expressed
and puri¢ed. These RNA inhibitors function by a unique
mechanism, distinct from that of small molecule protein
kinase inhibitors, which involves the steric exclusion of
substrate binding. Because these novel inhibitors interact
with less conserved structural aspects of their target kinase,
they could possess a much greater potential for speci¢city
than small molecule inhibitors of ATP binding.
Materials and methods
Protein production and puri¢cation
(His)6-tagged rat ERK2, human ERK1, and constitutively active human
MKK1 (G7B: vN4/S218D/S222D [27]) were separately expressed in Es-
cherichia coli BL21(DE3), pLYS-S and puri¢ed by nickel NTA-agarose
af¢nity chromotography as previously described [26,27]. In vitro activa-
tion of ERK1 and ERK2 by MKK1-G7B was performed as reported [28].
Activated murine p38K and activated rat JNK2 were produced in vivo by
coexpression with MEK4 and MEKK1C [29]. Myelin basic protein (MBP)
was purchased (Sigma) and the glutathione S-transferase/ELK1 fusion
protein (GST-ELK1 (307^428)) was expressed and puri¢ed as described
[30].
Library construction and RNA iterative selection
The initial RNA pool was produced by in vitro transcription of a DNA
library constructed as described [21]. This library had the general se-
quence 5P-AGCGAATTCTAATACGACTCACTATA//GGGAGAGCCATA-
CCTGAC-N68-CAGGTTACGCATCC-N66-GTCAGTCGTCAGGATCCG-
TG-3P, where N is a randomized nucleotide position and // represents
the T7 RNA polymerase transcriptional start site. Approximately 2U1014
members of this library (44 Wg) were transcribed with T7 RNA polymer-
ase. In the ¢rst selection cycle, approximately 82 Wg of the RNA pool
(representing four copies of each RNA) was denatured in water at 90³C
for 3 min and allowed to fold by slow cooling from 55³C to 30³C in
10 mM HEPES, pH 7.5, 10 mM MgCl2. After folding, the pool RNA
was passed through a nitrocellulose ¢lter (HAWP, Millipore Inc.) and
the ¢ltrate was incubated at a concentration of 2.5 WM with 0.2 WM
ppERK2 for 1 h at 30³C. RNA^protein complexes were collected by
passing this solution through another HAWP ¢lter. Bound RNA was
released from the ¢lter with 4 M guanidine thiocyanate, ethanol precipi-
tated, and ampli¢ed by reverse transcription and PCR. After the ¢fth
selection cycle, a negative selection step was introduced to remove
pool RNAs also retained on HAWP ¢lters in the presence of unphos-
phorylated ERK2. Four to six successive incubations and HAWP ¢ltra-
tions were used in each negative selection cycle. RNA and protein
concentrations were each progressively dropped to 1 nM in a total of
15 subsequent selection cycles. cDNA derived from the last selection
cycle was digested with EcoRI and HindIII and subcloned into similarly
digested pUC19. Family I and family II RNA sequences were deposited
in GenBank (accession numbers AF301132 and AF301133, respec-
tively). Dissociation constants were determined as described [31].
Activity assays and kinetic analysis
MAPK catalyzed in vitro phosphorylation reactions were monitored by
32P incorporation into either MBP or GST/ELK1 under conditions pre-
viously described [27]. Enzyme, substrate, and RNA inhibitor concen-
trations varied with experiment as indicated. Relative rates (krel) were
calculated by dividing kobs values obtained in the presence of RNA by a
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kobs value obtained in the absence of RNA but under otherwise identical
conditions.
RNA mutants and nuclease structure probing
Truncated RNAs were produced by a variety of approaches. Family I
v3P and family II v3P were obtained by run off transcription of pUC/family
I and pUC/family II, respectively, following their digestion with SfaNI, an
enzyme whose recognition site was designed into the central constant
region of the initial library. All other truncated RNA and mutant RNA
variants were transcribed with T7 RNA polymerase after their construc-
tion. TR-A was produced by polymerase extension of the overlapping
deoxyoligonucleotides TR-A/5P, 5P-AgC gAA TTC TAA TAC gAC TCA
CTA TAg gAA AgA CgC TAg CgA ATT ggT TCC TCg AAA gg and TR-
A/3P, 5P-ggA AAT TTT ggT TTC TTA ATA ACg CTT TCC CCT TTC gAg
gAA CCA ATT Cg. DNAs encoding A.1; A.2; A.1,2; B.1; B.2; B.1,2; B.3;
B.5; B.3,5; B.4; B.6 and B.4,6 were similarly produced, but deoxyoligo-
nucleotides carried the mutations indicated in Figure 8a. TR-D and TR-E
were produced by Milligan transcription [32] of deoxyoligonucleotides 5P-
GGA GTT TCT TAA TAA CGC TTT CCC CTT TCG AGG AAC TCC
TAT AGT GAG TCG TAT TAG AAT TCG CT and 5P-GGA AAT TTT
GGT TTC CCA ATT CGC TAG CGT CTT TCC TAT AGT GAG TCG
TAT TAG AAT TCG CT, respectively. TR-B was produced by priming
PCR of full length family II DNA with deoxyoligonucleotides 5P-AgC gAA
TTC TAA TAC gAC TCA CTA TAg ggA CgC TAg CgA ATT gg and 5P-
AAC gCT TTC CCC TAC. TR-C was produced by polymerase extension
of the overlapping deoxyoligonucleotides 5P-AgC gAA TTC TAA TAC
gAC TCA CTA TAg gAC CTg ACA AAg Acg CTg ATA AgC g and 5P-
ACC TgT CAA ATT TTg gTT TCT TAA TAA CGc TTA TcA Gcg Tc.
Computer predictions of RNA secondary structure were made using
Mulfold [23] running on an Apple G3 Powerbook. Prior to nuclease
structure probing experiments the concentration of RNase T1 (Sigma
Chemical Corp.), RNase T2 (CalBiochem, Inc.) and RNase V1 (Amer-
sham/Pharmacia Biotech Inc.) required for partial RNA digestion was
empirically determined.
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